Windlas Biotech's Q3 FY 2025-26 Quarterly Results
- 06 Feb 2026
Result Summary
- Windlas Biotech Ltd reported a 5.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 19.4%.
- Its expenses for the quarter were up by 7.5% QoQ and 21.8% YoY.
- The net profit decreased 15.7% QoQ and decreased 3.7% YoY.
- The earnings per share (EPS) of Windlas Biotech Ltd stood at 7.05 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 237.67 | 226.04 | 199.13 | 5.1% | 19.4% |
Total Expenses | 217.70 | 202.46 | 178.79 | 7.5% | 21.8% |
Profit Before Tax | 19.97 | 23.59 | 20.34 | -15.3% | -1.8% |
Tax | 4.97 | 5.79 | 4.76 | -14.2% | 4.4% |
Profit After Tax | 15.00 | 17.80 | 15.58 | -15.7% | -3.7% |
Earnings Per Share | 7.05 | 8.48 | 7.38 | -16.9% | -4.5% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Windlas Biotech Ltd is a company operating within the pharmaceutical manufacturing industry. The company specializes in the production of pharmaceutical formulations, which include a wide range of products such as solid and liquid dosage forms. Windlas Biotech is known for its contract manufacturing services and caters to both domestic and international markets. While specific recent developments or strategic initiatives are not available from the provided data, the company continues to focus on expanding its capabilities and enhancing its product offerings within the pharmaceutical sector.
Revenue
In the third quarter of the fiscal year 2026 (Q3FY26), Windlas Biotech Ltd reported a total income of ₹237.67 crores. This reflects a quarter-over-quarter (QoQ) increase of 5.1% from the previous quarter (Q2FY26), where the total income stood at ₹226.04 crores. Year-over-year (YoY) comparison shows a 19.4% increase in total income from Q3FY25, where it was ₹199.13 crores. The company's revenue growth indicates a consistent upward trend in its income over both the quarterly and annual periods.
Profitability
Windlas Biotech Ltd's profitability metrics for Q3FY26 include a profit before tax (PBT) of ₹19.97 crores, which represents a QoQ decrease of 15.3% from the PBT of ₹23.59 crores in Q2FY26. Year-over-year, the PBT decreased by 1.8% from ₹20.34 crores in Q3FY25. The company's tax expenses for Q3FY26 were ₹4.97 crores, reflecting a QoQ decrease of 14.2% and a YoY increase of 4.4%. The profit after tax (PAT) for Q3FY26 was ₹15.00 crores, showing a QoQ decline of 15.7% and a YoY decline of 3.7% from Q3FY25. Earnings per share (EPS) for Q3FY26 was ₹7.05, declining by 16.9% QoQ and 4.5% YoY.
Operating Metrics
In terms of operating expenses, Windlas Biotech Ltd's total expenses for Q3FY26 amounted to ₹217.70 crores, which is a 7.5% increase from the previous quarter (Q2FY26) where total expenses were ₹202.46 crores. Comparing this to the same quarter last year (Q3FY25), there is a 21.8% increase from expenses of ₹178.79 crores. The increase in expenses outpaced the growth in total income, resulting in a lower profit margin for the quarter. The financial data highlights the company's ongoing efforts to manage its operating costs amidst a growing revenue base.